Table 1.
Patient characteristics and incidence of TA-TMA
| Overall | Preprophylaxis implementation | Postprophylaxis implementation | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall, n (%) | One-year cumulative incidence of TA-TMA, % (95% CI) | P | Overall, n (%) | One-year cumulative incidence of TA-TMA, % (95% CI) | P | Overall, n (%) | One-year cumulative incidence of TA-TMA, % (95% CI) | P | |
| TA-TMA, Overall | 15/257 | 6.3 (3.2-9.4) | <.001 | 11/161 | 7.3 (3.2-11.4) | <.001 | 4/96 | 4.5 (0.2-8.8) | .84 |
| SR | 7/208 | 3.6 (1.1-6.1) | 4/135 | 3.2 (0.1-6.3) | 3/73 | 4.4 (0.1-9.3) | |||
| HR | 8/49 | 18.2 (6.8-29.6) | 7/26 | 28.2 (17.8-38.6) | 1/23 | 4.5 (0-13.1) | |||
| Age, y | .04 | .11 | .18 | ||||||
| <10 | 138 (54) | 3.1 (0.2-6) | 84 (52) | 3.8 (0.1-8.1) | 54 (56) | 2.1 (0.1-6.2) | |||
| ≥10 | 119 (46) | 9.8 (4.3-15.3) | 77 (48) | 10.9 (3.8-18) | 42 (44) | 7.8 (0.1-16.2) | |||
| Sex | .43 | .88 | .18 | ||||||
| Male | 151 (59) | 5.1 (1.4-8.8) | 94 (58) | 6.9 (1.6-12.2) | 57 (59) | 2 (0.1-5.9) | |||
| Female | 106 (41) | 7.9 (2.6-13.2) | 67 (42) | 7.9 (1.2-14.6) | 39 (41) | 8 (0.1-16.6) | |||
| Race | .34 | .30 | .12 | ||||||
| White | 181 (70) | 4.8 (1.5-7.9) | 111 (69) | 5.8 (1.3-10.3) | 70 (73) | 3.1 (0.1-7.4) | |||
| Black/African American | 20 (8) | 11.1 (0.1-25.5) | 10 (6) | 22.2 (0.1-49.4) | 10 (10) | 0 (0-32.1) | |||
| Asian American | 50 (20) | 10.5 (1.7-19.3) | 34 (21) | 9 (0.1-18.8) | 16 (17) | 14.1 (0.1-32.3) | |||
| Native American | 6 (2) | 0 (0-44.3) | 6 (4) | 0 (0-44.3) | 0 | — | |||
| Race/ethnicity | .98 | .75 | .9 | ||||||
| White | 83 (32) | 3.7 (0-9.2) | 53 (33) | 8.3 (0.5-16.1) | 30 (31) | 3.3 (2.7-3.9) | |||
| Hispanic and non-White | 174 (68) | 6.2 (2.5-9.9) | 108 (67) | 6.9 (2-11.8) | 66 (69) | 5 (0-10.5) | |||
| HSCT indication | .006 | .02 | .23 | ||||||
| Malignancy* | 157 (61) | 8.3 (3.8-12.8) | 94 (58) | 10.1 (3.8-16.4) | 63 (66) | 5.3 (0.1-11.2) | |||
| SAA | 17 (7) | 17.6 (0-35.6) | 10 (6) | 20 (0-44.7) | 7 (7) | 14.3 (0.1-40.2) | |||
| Other nonmalignant† | 83 (32) | 0 (0-5.3) | 57 (36) | 0 (0-7.6) | 26 (27) | 0 (0-15.2) | |||
| Recipient CMV serostatus | .03 | .12 | .14 | ||||||
| Positive | 120 (47) | 9.9 (4.2-15.6) | 80 (50) | 10.6 (3.7-17.5) | 40 (41) | 8.4 (0.1-17.6) | |||
| Negative/unknown‡ | 137 (53) | 3.1 (0.2-6) | 81 (50) | 4 (0-8.3) | 56 (58) | 1.9 (0.1-5.4) | |||
*
Three patients with lymphoma had prior autologous transplants (2008, 2013, and 2015).
†
Immunodeficiencies (n = 41), bone marrow failure syndromes (n = 12), hemoglobinopathies (n = 8), hemophagocytic lymphohistiocytosis (n = 8), metabolic disorders (n = 11), and osteopetrosis (n = 3).
‡
Patients unable to make specific antibodies without prior CMV infection.